The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Open accessAbstract
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Cai, Q., Yang, M., Liu, D., Chen, J., Shu, D., Xia, J., Liao, X., Gu, Y., Cai, Q., Yang, Y., et al. (2020) · Engineering · doi:10.1016/j.eng.2020.03.007 · Cited by 1,357
RetractedWang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020) · Cell Research · doi:10.1038/s41422-020-0282-0 · Cited by 6,958
Sample size tables for exact single‐stage phase II designs
A'Hern, R. P. (2001) · Statistics in Medicine · doi:10.1002/sim.721 · Cited by 399
A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?
Pilkington, V., Pepperrell, T., & Hill, A. (2020) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30016-9 · Cited by 271
Cited by
Drug treatments for covid-19: living systematic review and network meta-analysis
Siemieniuk, R. A., Bartoszko, J. J., Zeraatkar, D., Kum, E., Qasim, A., Díaz Martinez, J. P., Izcovich, A., Rochwerg, B., Lamontagne, F., Han, M. A., et al. (2020) · BMJ · doi:10.1136/bmj.m2980 · Cited by 846
Udwadia, Z. F., Singh, P., Barkate, H., Patil, S., Rangwala, S., Pendse, A., Kadam, J., Wu, W., Caracta, C. F., & Tandon, M. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.11.142 · Cited by 282
Hassanipour, S., Arab-Zozani, M., Amani, B., Heidarzad, F., Fathalipour, M., & Martinez-de-Hoyo, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-90551-6 · Cited by 264
Zeraatkar, D., Pitre, T., Leung, G., Cusano, E., Agarwal, A., Khalid, F., Escamilla, Z., Cooper, M. A., Ghadimi, M., Wang, Y., et al. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2022-000309 · Cited by 44
Metadata
- Authors
- Ivashchenko, A. A., Dmitriev, K. A., Vostokova, N. V., Azarova, V. N., Blinow, A. A., Egorova, A. N., Gordeev, I. G., Ilin, A. P., Karapetian, R. N., Kravchenko, D. V., Lomakin, N. V., Merkulova, E. A., Papazova, N. A., Pavlikova, E. P., Savchuk, N. P., Simakina, E. N., Sitdekov, T. A., Smolyarchuk, E. A., Tikhomolova, E. G., Yakubova, E. V., & Ivachtchenko, A. V.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-09
- Volume
- 73
- Issue
- 3
- Pages
- 531-534
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W3048223030
- Cited by
- 255
- References
- 4
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. https://app.cochat.ai/papers/10.1093/cid/ciaa1176
- The paper
- Ivashchenko, A. A., Dmitriev, K. A., Vostokova, N. V., Azarova, V. N., Blinow, A. A., Egorova, A. N., Gordeev, I. G., Ilin, A. P., Karapetian, R. N., Kravchenko, D. V., Lomakin, N. V., Merkulova, E. A., Papazova, N. A., Pavlikova, E. P., Savchuk, N. P., Simakina, E. N., Sitdekov, T. A., Smolyarchuk, E. A., Tikhomolova, E. G., . . . Ivachtchenko, A. V. (2021). AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa1176
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.